Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants

Lupus

Volumn 16, Issue 8, 2007, Pages 651-656

  Biggioggero, M ^a   Borghi, M O ^a   Gerosa, M ^a   Trespidi, L ^b   Cimaz, R ^c   Meroni, P L ^a,d  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Autoimmunity; Immunosuppressive therapy; Neonatal immune system; Pregnancy

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; DEXAMETHASONE; GAMMA INTERFERON; HEPATITIS B VACCINE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2;

ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNE DISEASE; BLOOD CELL COUNT; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; HUMAN; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MALE; PRENATAL EXPOSURE; PRIORITY JOURNAL; SEROLOGY;

ANTIGENS, CD; AUTOIMMUNE DISEASES; AZATHIOPRINE; CYCLOSPORINE; CYTOKINES; DEXAMETHASONE; FEMALE; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; INFANT, NEWBORN; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTES; MALE; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 34548430129     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307079569     Document Type: Article

References (44)

1. Little BB. Immunosuppressant therapy during gestation. Seminars Perinatol 1997; 21: 143-148.
2. Polifka JE, Friedman JM. Teratogen update: Azathioprine and 6-Mercaptopurine. Teratol 2002; 65: 240-261.
3. Rahman P, Gladman DD, Urowitz MB. Clinical predictors of fetal outcome in systemic lupus erythematosus. J Rheumatol 1998; 25: 1526-1530.
4. Tendron A, Gouyon JB, Decramer S. In utero exposure to immunosuppressive drug: experimental and clinical studies. Pediatr Nephrol 2002; 17: 121-130.
5. Griffin J. Rheumatoid arthritis: biological effects and management. In: Scott JS, Bird HA eds. Pregnancy, autoimmunity, and connective tissue disorders. Oxford: Oxford University Press, 1990: 140-162.
6. Mintz G, Niz J, Gutierrez G et al. Prospective study of pregnancy in systemic lupus erythematosus. Result of a multidisciplinary approach. J Rheumatol 1986; 13: 732-739.
7. Ostensen M. Rheumatologic disorders. Best Pract Res Cl Ob Gynaecol 2001; 15: 953-969.
8. Petri M. Immunosuppressive drug use in pregnancy. Autoimmunity 2003; 36: 51-56.
9. Harris EN. Antirheumatic drugs in pregnancy. Lupus 2002; 11: 683-689.
10. Takahashi N, Nishida H, Hoshi J. Severe B cell depletion in newborns from renal transplant mothers taking immunosuppressive agents. Transplantation 1994; 57: 1617-1621.
11. Di Paolo S, Schena A. Morrone LF et al. Immunological evaluation during the first year of life of infants born to cyclosporine-treated female kidney transplant recipient. Trasplantation 2000; 69: 2049-2054.
12. Cimaz R, Meregalli E, Biggioggero M et al. Alterations in the immune system of children from mothers treated with immunosuppressive agents during pregnancy. Toxicol Lett 2004; 149: 155-162.
13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
14. Doria A, Mosca M, Gambari PF, Bombardieri S. Defining unclassifiable connective tissue diseases: incomplete, undifferentiated or both? J Rheumatol 2005; 32: 213-215.
15. Miyakis S, Lockshin D, Atsumi T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. J Thromb Haemostasis 2006, 4: 295-306.
16. Vitali C, Bombardieri S, Moutsopulos HM et al. Preliminary criteria for the classification of Sjogren syndrome: results of a prospective concerted action supported by the European community. Arthritis Rheum 1993; 36: 340-347.
17. Baloch Z, Carayon P, Conte-Devolx B et al. Guidelines Committee, National Academy of Clinical Biochemistry. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003; 13: 3-126.
18. Stites DP, Stobo JD, Wells JV. Basic and clinical immunology. 7th edition. Los Altos, CA: Appleton & Lange, 1991.
19. Redmond GP. Physiological changes during pregnancy and their implications for pharmacological treatment. Clin Invest Med 1985; 8: 317-322.
20. Armenti VT, Moritz MJ, Davison JM. Drug safety issues in pregnancy following transplantation and immunosuppression. Effects and outcomes. Drug Saf 1998; 19: 219-232.
21. Ersay A, Oygür N, Cpskun M, Suleymanlar G, Track B, Yegin O. Immunologic evaluation of a neonate born to an immunosuppressed kidney transplant recipient. Am J Perinatol 1995; 12: 413.
22. Bassily M, Ghabrial H, Smallwood RA et al. Determinants of placental drug transfer: studies in the isolated perfused human placenta. J Pharm Sci 1995; 84: 1054-1060.
23. Bourget P, Roulot C, Fernandez H. Models for placental transfer studies of drugs. Clin Pharmacokinet 1995; 28: 161-180.
24. Ostensen M, Khamashta M, Lockshin M, et al., Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006; 8: 209.
25. Ramsey-Goldman R, Schilling E. Immunosuppressive drug use during pregnancy. Rheum Dis Clin North Am 1997; 23: 149-167.
26. Benediktsson R, Calder AA, Edwards CRW, Seckl JR. Placental 11b-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure. Clin Endocrinol 1997; 46: 161-166.
27. Spinillo A, Viazzo F, Colleoni R, Chiara A, Cerbo RA, Fazzi E. Two-year infant neurodevelopmental outcome after single or multiple antenatal courses of corticosteroids to prevent complications of prematurity. Am J Obstet Gynecol 2004; 191: 217-224.
28. Saleeb S, Copel J, Friedman D et al. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthritis Rheum 1999; 42: 2335-2345.
29. Airò P, Scarsi M, Brucato A et al. Characterization of T-cell population in children with prolonged fetal exposure to dexamethasone for anti-Ro/SS-A antibodies associated congenital heart block. Lupus 2006; 15: 553-561.
30. Nandakumaran M, Eldeen AS. Transfer of cyclosporine in the perfused human placenta. Dev Pharmacol Ther 1990; 15: 101-105.
31. Venkataramanan R, Koneru B, Wang CCP, Burckart GJ, Caritis SN, Starzl TE. Cyclosporine and its metabolites in mother and baby. Transplantation 1988; 46: 468.
32. Armenti VT, Ahlswede KM, Ahlswede BA et al. National transplantation pregnancy registry: outcomes of 154 pregnancies in cyclosporine-treated female kidney transplant recipients. Transplantation 1994; 57: 502-506.
33. Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001; 71: 1051-1055.
34. Jain A, Venkataramanan R, Fung JJ et al. Pregnancy after liver transplantation under tacrolimus. Transplantation 1997; 64: 559-565.
35. Kainz A, Harabacz I, Cowlrick IS, Shirikant DG, Hagiwara D. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation 2000; 70: 1718-1721.
36. Pilarski LM, Yacyshyn BR, Lazarovits AI. Analysis of peripheral blood lymphocyte populations and immune function from children exposed to cyclosporine or to azathioprine in utero. Transplantation 1994; 57: 133-144.
37. DeWitte DB, Buick MK, Cyran SE. Neonatal pancytopenia and severe combined immunodeficiency associated with antenatal administration of azathioprine and prednisone. J Pediatr 1984; 105: 625-628.
38. Janssen NM, Genta M. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med 2000; 160: 610-619.
39. Prévot A, Martini S, Guignard JP. In utero exposure to immunosuppressive drugs. Biol Neonate 2002; 81: 73-81.
40. Airò P, Antonioli CM, Motta M et al. The immune development in a child born to a cyclosporine A-treated woman with systemic lupus erythematosus/polymyositis. Lupus 2002; 11: 454-457.
41. Chaouat G, Diallo GT, Volumenie JL et al. Immune suppression and Th1/Th2 balance in pregnancy revisited: a (very) personal tribute to Tom Wegmann. AJRI 1997; 37: 427-434.
42. Gitau R, Cameron A, Fisk NM et al. Foetal exposure to maternal cortisol. Lancet 1985; 352: 707-708.
43. Claris O, Picaud JC, Brazier JL, Salle BL. Pharmacokinetics of cyclosporin A in 16 newborn infants of renal or cardiac transplant mothers. Dev Pharmacol Ther 1993; 20: 180-185.
44. Scott JR. Risks to the children born to mothers with autoimmune disease. Lupus 2002; 11: 655-660.